


THE PRAVIN AGARWAL FOUNDATION

January Newsletter 2026

As January 2026 arrives with fresh beginnings and renewed hope, The Pravin Agarwal Foundation (TPAF) continues to ignite hope and transform lives through pediatric liver transplants. With over 650+ children given a second chance at life, including strong momentum from our efforts in 2024-25, we're charging toward a world where no child is denied care due to financial barriers. This month, we celebrate our shared progress, reflect on the miracles of the past year, and invite you to join us in fueling even more life-changing stories in the year ahead!


Happy New Year from the TPAF family, here's to more hope, more healing, and more miracles in 2026!

A Decade of Miracles: Celebrating 10 Years of The Pravin Agarwal Foundation

As January 2026 dawns with fresh hope and gratitude, we proudly mark a monumental milestone, 10 incredible years since The Pravin Agarwal Foundation was founded in 2016 by visionary philanthropist Pravin Agarwal. What began as a heartfelt mission to make pediatric liver transplants affordable and accessible for every child in need has blossomed into a powerful movement of compassion, innovation, and life-changing impact. From enabling just 15 PLTs in our early days to supporting over 650+ children with life-saving pediatric liver transplants and Kasai procedures today, TPAF has transformed the pediatric liver care ecosystem in India.

This 10-year journey is a true achievement of collective will, proving that when vision, perseverance, and community come together, barriers fall and miracles multiply. We have turned despair into hope for hundreds of families, ensured no child is denied care due to financial hardship, and empowered early detection and prevention across communities. As we celebrate this decade of dedication, we look ahead with even greater ambition: in the coming years, TPAF is set to reach greater PLTs milestone and continue building a future where every child thrives.

Thank you to every donor, partner, doctor, trustee, and well-wisher who has been part of this extraordinary story.



Our Commitment and Impact

Together with over 26 hospital partners, dedicated doctors, and our incredible supporters, TPAF continues to strive toward a brighter future for children battling liver disease. As we embrace the fresh hope of January 2026, our commitment remains stronger than ever. This year, we proudly stand by our mission to:

Facilitate timely medical interventions through pediatric liver transplants and Kasai procedures.

Provide essential financial support to remove overwhelming cost barriers for families.

Empower communities with knowledge for early detection, timely treatment, and prevention of advanced liver conditions.

With over 650+ children already given the gift of a second chance at life through our collective efforts, we are more determined than ever to reach further, partner stronger, and ensure no child is left behind.

The lives we touched....



Shreyansh Pawar

Meet Shreyansh Pawar, a 4-year-old boy whose courage and family's love have turned a difficult journey into one of hope and healing. Diagnosed with Budd-Chiari syndrome complicated by severe Hepatopulmonary Syndrome (HPS), Shreyansh faced a life-threatening liver condition that made finding a suitable donor extremely challenging. Despite repeated efforts with his parents and even exploring the cadaveric liver option, no match was found in time. Then, in a beautiful act of love, his devoted grandmother stepped forward, got tested, and was found to be a perfect match. With incredible selflessness and courage, she donated part of her liver, enabling Shreyansh to receive his life-saving pediatric liver transplant. The surgery was successful, and today the little 4-year-old is recovering steadily, breathing easier, and beginning to embrace a healthier, brighter future.



Iqra Khatoon

Meet Iqra Khatoon, a brave 1-year-old girl from Bihar whose quiet strength has touched many hearts. Diagnosed with Biliary Atresia, she faced a serious liver condition compounded by heartbreak when her father's family refused financial support simply because she is a girl. Undeterred, her devoted parents showed extraordinary determination and love, arranging her life-saving pediatric liver transplant at Gleneagles Hospital, Mumbai. The successful surgery has given Iqra a fresh start, and she is now healing beautifully, growing stronger with each passing day. Iqra's journey is a powerful reminder of how unwavering parental resolve, timely medical care, and community support can overcome even the toughest barriers, ensuring every child, regardless of gender or circumstance, gets the chance to thrive and embrace a healthy future.

Industry Update

Screening and diagnosis of metabolic dysfunction-associated steatotic liver disease in children within public healthcare

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) has increased rapidly. NASPGHAN recommends screening children at risk for MASLD, but its implementation remains unclear. We explored the implementation of screening in healthcare.

Methods

Data were collected from 908 children (median 11.4 years, 42.7% girls) investigated for overweight/obesity. Emphasis was placed on screening methods, diagnosis and potential secular changes. The diagnosis was confirmed retrospectively using novel criteria.

Results

Investigations included measuring alanine aminotransferase (ALT) in 83.1%, ultrasonography in 9.1%, and no screening in 16.5%. Screening was conducted in 86.2% of children meeting the recommendations, but 69.3% of those not eligible, mostly due to young age, were also screened. Screening was more frequent in tertiary care. Overall, 87.9% were tested for metabolic comorbidities and 80.9% underwent differential diagnostics, with 5.7% having other liver-affecting diseases/medications. ALT testing increased in tertiary care from 81.9% in 2002-2011 to 91.4% in 2012-2020 ($p < 0.001$), and exclusion of liver-affecting conditions improved in both tertiary (79.6% vs. 87.4%, $p = 0.017$) and primary care (61.5% vs. 84.6%, $p < 0.001$). MASLD was diagnosed clinically in 7.4%, while 14.5% met the criteria retrospectively.

Conclusions

MASLD screening practices are mostly aligned with the recommendations. However, many patients remain unrecognized, underscoring the need for better guidelines.

Impact

In a large cohort of 3-17-year-old children investigated in healthcare due to obesity, implementation of

- MASLD screening largely aligned with current recommendations supporting general acceptance of screening.

Screening was conducted in 86.2% of children meeting the NASPGHAN screening recommendations, while

- 87.9% were also tested for metabolic comorbidities, and 80.9% underwent differential diagnostics.

MASLD was diagnosed clinically in 7.4%, while 14.5% met the criteria retrospectively, suggesting possible

- underdiagnosis.

Compared to NASPGHAN guidelines, screening appeared excessive among younger children. Nevertheless,

- MASLD was also prevalent in this age group, indicating a need for further research to determine optimal age thresholds.
-

Support us by Volunteering, Donating or Spreading the message

Amplify

We warmly invite you to join us in strengthening and amplifying our efforts.

www.tpaf.in

Assistance

If you have any query, need any support or would simply like to have a conversation, reach out to us on

info@tpaf.in | +91- 7768853030

Rate our newsletter-click the [link](#)

